Early Detection of Local Tumor Progression after Irreversible Electroporation (IRE) of a Hepatocellular Carcinoma Using Gd-EOB-DTPA-Based MR Imaging at 3T.
Gd-EOB-DTPA
early detection
hepatocellular carcinoma
irreversible electroporation
magnetic resonance imaging
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
30 Mar 2021
30 Mar 2021
Historique:
received:
28
12
2020
revised:
27
03
2021
accepted:
29
03
2021
entrez:
3
4
2021
pubmed:
4
4
2021
medline:
4
4
2021
Statut:
epublish
Résumé
This single-center retrospective study was conducted to improve the early detection of local tumor progression (LTP) after irreversible electroporation (IRE) of a hepatocellular carcinoma (HCC) using gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-based 3T MR imaging and to identify helpful signal characteristics by comparing 23 patients with and 60 patients without LTP. To identify the differences in the sensitivity of MRI sequences, the specificity, positive prediction value, negative prediction value (NPV) and diagnostic odds ratio were calculated. A chi-squared test, two-tailed student's t-test and binary logistic regression model were used to detect distinct patient characteristics and variables for the prediction of LTP. LTP was mostly detected in the peripheral ablation zone (82.6%) within the first six months (87.0%). The central LTP ablation area presented more hypointensities in T1 p.v. (sensitivity: 95.0%; NPV: 90.0%) and in T1 d.p. (sensitivity: 100.0%; NPV: 100.0) while its peripheral part showed more hyperintensities in T2 BLADE (sensitivity: 95.5%; NPV: 80.0%) and in diffusion sequences (sensitivity: 90.0%). Liver cirrhosis seems to be an unfavorable prognosticator for LTP (
Identifiants
pubmed: 33808336
pii: cancers13071595
doi: 10.3390/cancers13071595
pmc: PMC8037433
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Vasc Interv Radiol. 2011 Jul;22(7):947-51
pubmed: 21550820
Radiology. 2000 Dec;217(3):633-46
pubmed: 11110923
Technol Cancer Res Treat. 2007 Feb;6(1):37-48
pubmed: 17241099
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
Exp Clin Transplant. 2017 Mar;15(Suppl 2):31-35
pubmed: 28301996
Eur Radiol. 2020 Jan;30(1):186-194
pubmed: 31372783
J Vasc Interv Radiol. 2014 Nov;25(11):1706-8
pubmed: 25442133
PLoS One. 2013 Nov 01;8(11):e76260
pubmed: 24223700
Radiology. 2017 Sep;284(3):877-886
pubmed: 28453431
Cardiovasc Intervent Radiol. 2010 Feb;33(1):11-7
pubmed: 19924474
Interv Med Appl Sci. 2014 Dec;6(4):147-53
pubmed: 25598987
J Surg Oncol. 2017 May;115(6):704-710
pubmed: 28493544
Radiology. 2016 Jan;278(1):285-94
pubmed: 26523493
J Vasc Interv Radiol. 2015 May;26(5):694-702
pubmed: 25812712
J Clin Med. 2018 Dec 25;8(1):
pubmed: 30585195
Radiology. 2007 Sep;244(3):776-83
pubmed: 17690322
J Hepatocell Carcinoma. 2016 Oct 05;3:41-53
pubmed: 27785449
Radiology. 2014 Sep;272(3):635-54
pubmed: 25153274
Cureus. 2019 Jun 25;11(6):e4994
pubmed: 31497425
Hepatology. 2018 Jan;67(1):401-421
pubmed: 28859233
J Am Coll Surg. 2012 Sep;215(3):379-87
pubmed: 22704820
PLoS One. 2014 Jun 20;9(6):e100315
pubmed: 24950259
J Magn Reson Imaging. 1998 Jan-Feb;8(1):40-7
pubmed: 9500259
Hepatogastroenterology. 2003 Nov-Dec;50(54):1991-5
pubmed: 14696450
Sci Rep. 2020 Dec 14;10(1):21902
pubmed: 33318515
PLoS One. 2015 Aug 13;10(8):e0135773
pubmed: 26270651
Technol Cancer Res Treat. 2013 Jun;12(3):233-41
pubmed: 23369152
Invest Radiol. 2012 Nov;47(11):671-5
pubmed: 23037001
J Vasc Interv Radiol. 2011 May;22(5):611-21
pubmed: 21439847
Radiology. 2014 Oct;273(1):241-60
pubmed: 24927329
J Surg Oncol. 2013 Apr;107(5):544-9
pubmed: 23090720
Hepatology. 2011 Mar;53(3):1020-2
pubmed: 21374666
Radiology. 2010 May;255(2):426-33
pubmed: 20413755
Semin Oncol. 2002 Apr;29(2):107-18
pubmed: 11951208
Cardiovasc Intervent Radiol. 2019 Apr;42(4):584-590
pubmed: 30697637